» Articles » PMID: 7859939

Contribution of Hepatic Glycogenolysis to Glucose Production in Humans in Response to a Physiological Increase in Plasma Glucagon Concentration

Overview
Journal Diabetes
Specialty Endocrinology
Date 1995 Feb 1
PMID 7859939
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The contribution of net hepatic glycogenolysis to overall glucose production during a physiological increment in the plasma glucagon concentration was measured in six healthy subjects (18-24 years, 68-105 kg) after an overnight fast. Glucagon (approximately 3 ng.kg-1.min-1), somatostatin (0.1 microgram.kg-1.min-1), and insulin (0.9 pmol.kg-1.min-1) were infused for 3 h. Liver glycogen concentration was measured at 15-min intervals during this period using 13C-labeled nuclear magnetic resonance spectroscopy, and liver volume was assessed from magnetic resonance images. The rate of net hepatic glycogenolysis was calculated from the decrease in liver glycogen concentration over time, multiplied by the liver volume. The rate of glucose appearance (Ra) was calculated from [3-3H]glucose turnover data using a two-compartment model of glucose kinetics. Plasma glucagon concentration rose from 136 +/- 18 to 304 +/- 57 ng/l and plasma glucose concentration rose from 5.6 +/- 0.1 to 10.4 +/- 0.9 mmol/l on initiation of the infusions. Mean baseline Ra was 11.8 +/- 0.4 mumol.kg-1.min-1, increased rapidly after the beginning of the infusions, reaching its highest value after 20-40 min, and returned to baseline by 140 min. Liver glycogen concentration decreased almost linearly (from 300 +/- 19 mmol/l liver at baseline to 192 +/- 20 mmol/l liver at t = 124 min) during 2 h after the beginning of the infusions, and the calculated mean rate of net hepatic glycogenolysis was 21.7 +/- 3.6 mumol.kg-1.min-1. Mean Ra during the same time period was 22.8 +/- 2.3 mumol.kg-1.min-1. Thus, net hepatic glycogenolysis accounted for 93 +/- 9% of Ra.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.

Gray S, Goonatilleke E, Emrick M, Becker J, Hoofnagle A, Stefanovski D Diabetes. 2023; 73(3):412-425.

PMID: 38015721 PMC: 10882148. DOI: 10.2337/db23-0201.


Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases.

Haedersdal S, Andersen A, Knop F, Vilsboll T Nat Rev Endocrinol. 2023; 19(6):321-335.

PMID: 36932176 DOI: 10.1038/s41574-023-00817-4.


Protein Ingestion in Reducing the Risk of Late-Onset Post-Exercise Hypoglycemia: A Pilot Study in Adolescents and Youth with Type 1 Diabetes.

Paramalingam N, Keating B, Chetty T, Fournier P, Soon W, ODea J Nutrients. 2023; 15(3).

PMID: 36771250 PMC: 9920079. DOI: 10.3390/nu15030543.


A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity.

Vega R, Whytock K, Gassenhuber J, Goebel B, Tillner J, Agueusop I J Endocr Soc. 2021; 5(9):bvab118.

PMID: 34337278 PMC: 8317630. DOI: 10.1210/jendso/bvab118.


Glucagon Regulation of Energy Expenditure.

Kleinert M, Sachs S, Habegger K, Hofmann S, Muller T Int J Mol Sci. 2019; 20(21).

PMID: 31671603 PMC: 6862306. DOI: 10.3390/ijms20215407.